ACE2 mRNA overexpression has been reported in patients with comorbidities (hypertension, diabetes, obesity, ischemic cardiomyopathy, among others) who are at higher risk of a more severe COVID‐19.5, 6. Here, ACE2 is linked to obesity due to melanocortin 4 receptor deficiency.